Registry following adults with plasma cell disorders, including multiple myeloma
Records health assessments in adults with plasma cell disorders, such as multiple myeloma.
Plain-language title generated from the registry record
Registry title: Registry for Adults With Plasma Cell Disorders (PCD's)
Key facts
- Where
- Chapel Hill, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a plasma cell disorder, such as multiple myeloma, who are treated at UNC Cancer Hospitals or partner sites and will complete an assessment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A documented plasma cell disorder: a monoclonal protein and/or a monoclonal plasma cell population in the blood or marrow. Examples are smoldering myeloma, active multiple myeloma, plasma cell leukemia, amyloidosis and POEMS syndrome.
Main reasons for not taking part
- Physical or mental health problems that the treating doctor feels would prevent taking part successfully
- Cannot read and speak English
- Does not agree to complete the assessment at the start and at follow-up visits
Read by machine on 9 November 2026.
Where in United States
- North Carolina Cancer HospitalChapel Hill, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Trial code
- NCT03717844
- Record updated
- 20 November 2025
- Original description
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).Read full original descriptionShow less
Registry for Adults With Plasma Cell Disorders (PCD's)
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).
Inclusion: Patients have an outpatient appointment or are hospitalized inpatient at UNC Cancer Hospitals, or affiliated clinic settings or participating sites for the evaluation and management of a PCD; Patients have a documented diagnosis of PCD defined as the presence of a monoclonal protein and/or monoclonal plasma cell population. Examples of PCDs include but are not limited to monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple (active) myeloma; plasma cell leukemia; Castleman's disease; amyloidosis; light and/or heavy chain deposition disease; Polyneuropathy, Organomegaly, Endocrinopathy,Monoclonal gammopathy and Skin changes (POEMS) syndrome; and cryoglobulinemia; Age ≥18 years; Must consent to participation in this study and agree to complete the assessment at baseline and follow-up time points; Must be able to read and speak English.
Exclusion: Physical or psychiatric/behavioral illnesses or problems that the treating clinician feels would preclude successful participation in the study; There are no imaging or lab studies required to determine eligibility.